Horizon Pharma plc Form 8-K January 12, 2016

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

## FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

**Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): January 12, 2016

**Horizon Pharma Public Limited Company** 

(Exact name of registrant as specified in its charter)

Ireland 001-35238 Not Applicable

(State or other jurisdiction (Commission File No.) (IRS Employer Identification No.)

of incorporation)

Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland

(Address of principal executive offices)

# Edgar Filing: Horizon Pharma plc - Form 8-K

# Registrant s telephone number, including area code: 011-353-1-772-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 2.02 Results of Operations and Financial Condition.

On January 12, 2016, in advance of meetings and its presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Horizon Pharma plc (the Company) is making publicly available a corporate presentation that includes estimates of total prescriptions of certain of the Company s products for the fourth quarter and full year 2015, as all as other updates regarding its business. The presentation is available through the Company s website and a copy is attached as Exhibit 99.1 hereto.

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Presentation of Horizon Pharma plc, made available on January 12, 2016.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2016

HORIZON PHARMA PUBLIC LIMITED

COMPANY

/s/ Paul W. Hoelscher
By: \_\_\_\_\_

Paul W. Hoelscher

Executive Vice President, Chief Financial Officer